A Phase 2 interventional study of Acetylsalicylic acid and Rivaroxaban in Acute Coronary Syndrome, sponsored by Janssen Research & Development, LLC. Completed at 262 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-26.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing rivaroxaban in Acute Coronary Syndrome — 2 open to participants now, 2 under way, none of them phase 3. Rivaroxaban · Acute Coronary Syndrome.
Among the 13 studies testing rivaroxaban in Acute Coronary Syndrome, this one is the 4th largest by enrollment, is the only one that started in 2015, is one of 3 in phase 2, and was the 4th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.
Browse Acute Coronary Syndrome studies →2 of the 13 studies testing rivaroxaban in Acute Coronary Syndrome are open now, in 2 countries. Recruiting first, the newest first:
Instituto Nacional de Cardiologia Ignacio Chavez · Sites in Mexico
Ages 18–80
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–75
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,037 is above the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 261 across the 13 interventional studies. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 13 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
Johnson & Johnson has 4 studies filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies testing rivaroxaban in Acute Coronary Syndrome that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05638867China National Center for Cardiovascular DiseasesNOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing rivaroxaban in Acute Coronary Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to estimate the risk of bleeding with rivaroxaban, compared with acetylsalicylic acid (ASA), in addition to a single antiplatelet/ platelet adenosine diphosphate P2Y12 receptor antagonist (P2Y12 inhibitor agent: clopidogrel or ticagrelor), in participants with a recent acute coronary syndrome (ACS: including ST segment elevation myocardial infarction [STEMI] and non-ST-segment elevation acute coronary syndrome [NSTE-ACS]).
This is a prospective, randomized (the study drug is assigned by chance), double-blind (neither physician nor participant knows the treatment that the participant receives), active-controlled (study in which the experimental treatment or procedure is compared to a standard treatment or procedure), parallel group (each group of participants will be treated at the same time), multicenter (when more than one hospital or medical school team work on a medical research study) study in participants with a recent ACS (STEMI or NSTE-ACS). All the eligible participants receiving background treatment of ASA plus clopidogrel (Stratum 1) or ASA plus ticagrelor (Stratum 2) will be randomly assigned to either receive ASA or rivaroxaban on background of P2Y12 receptor antagonists treatment. This study will include 3 phases: Screening Phase (up to 10 days, before study start on Day 1), Double-blind Treatment Phase (up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier), and Follow-up Phase (up to 30 days). Participants' safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Acetylsalicylic acid (ASA) 100 milligram (mg) enteric-coated tablet once daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
Drug: Acetylsalicylic acid · Drug: Clopidogrel
Rivaroxaban 2.5 mg tablet twice daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
Drug: Rivaroxaban · Drug: Clopidogrel
ASA 100 mg enteric-coated tablet once daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
Drug: Acetylsalicylic acid · Drug: Ticagrelor
Rivaroxaban 2.5 mg tablet twice daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
Drug: Rivaroxaban · Drug: Ticagrelor
ASA 100 mg enteric-coated tablet once daily orally.
Also known as: Aspirin
Rivaroxaban 2.5 mg tablet twice daily orally.
Also known as: JNJ-39039039, Bay 59-7939, Xarelto
Clopidogrel 75 mg once daily orally.
Also known as: Plavix
Ticagrelor 90 mg twice daily orally.
Also known as: Brilinta
Number of Participants With Non Coronary Artery Bypass Graft-Related (Non CABG-related) Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events
Non CABG-related TIMI clinically significant bleeding events are sum of non CABG-related TIMI major bleeding events, TIMI minor bleeding events and TIMI bleeding events requiring medical attention. Major: any symptomatic intracranial bleeding: clinically overt signs of hemorrhage with hemoglobin (Hb) drop of greater than or equal to (\>=)5 gram per deciliter (g/dl) (or absolute drop in hematocrit of \>=15%) and fatal bleeding (results in death within 7 days); Minor: clinically overt sign of hemorrhage with Hb drop of 3 - \<5 g/dl (or drop in hematocrit of 9 - \<15%); requiring medical attention: bleeding event that required medical, surgical treatment/laboratory evaluation and did not meet criteria for major/minor bleeding event.
Time frame: From start of study treatment until follow-up (up to 390 days)
| Milestone | Rivaroxaban 2.5 mg Twice Daily (BID) | Acetylsalicylic Acid 100 mg Once Daily (OD) |
|---|---|---|
| Started | 1519 | 1518 |
| Treated | 1510 | 1506 |
| Completed | 1510 | 1511 |
| Not completed | 9 | 7 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 8 | 7 |
Non CABG-related TIMI clinically significant bleeding events are sum of non CABG-related TIMI major bleeding events, TIMI minor bleeding events and TIMI bleeding events requiring medical attention. Major: any symptomatic intracranial bleeding: clinically overt signs of hemorrhage with hemoglobin (Hb) drop of greater than or equal to (\>=)5 gram per deciliter (g/dl) (or absolute drop in hematocrit of \>=15%) and fatal bleeding (results in death within 7 days); Minor: clinically overt sign of hemorrhage with Hb drop of 3 - \<5 g/dl (or drop in hematocrit of 9 - \<15%); requiring medical attention: bleeding event that required medical, surgical treatment/laboratory evaluation and did not meet criteria for major/minor bleeding event.
| participants | Rivaroxaban 2.5 mg Twice Daily (BID) | Acetylsalicylic Acid 100 mg Once Daily (OD) |
|---|---|---|
| Number of Participants With Non Coronary Artery Bypass Graft-Related (Non CABG-related) Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events | 80 | 74 |
Collected over Up to 390 days. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivaroxaban 2.5 mg Twice Daily (BID) | — | 125/1,510 (8.3%) | 81/1,510 (5.4%) |
| Acetylsalicylic Acid 100 mg Once Daily (OD) | — | 138/1,506 (9.2%) | 84/1,506 (5.6%) |
| Event | Rivaroxaban 2.5 mg Twice Daily (BID) | Acetylsalicylic Acid 100 mg Once Daily (OD) |
|---|---|---|
| Cardiac FailureCardiac disorders | 9/1510 | 7/1506 |
| Atrial FibrillationCardiac disorders | 3/1510 | 7/1506 |
| PneumoniaInfections and infestations | 7/1510 | 5/1506 |
| Angina UnstableCardiac disorders | 5/1510 | 5/1506 |
| Cholecystitis AcuteHepatobiliary disorders | 3/1510 | 5/1506 |
| Hypertensive CrisisVascular disorders | 5/1510 | 2/1506 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/1510 | 4/1506 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 0/1510 | 4/1506 |
| Coronary Artery RestenosisInjury, poisoning and procedural complications | 1/1510 | 3/1506 |
| SyncopeNervous system disorders | 2/1510 | 3/1506 |
| Event | Rivaroxaban 2.5 mg Twice Daily (BID) | Acetylsalicylic Acid 100 mg Once Daily (OD) |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 33/1510 | 39/1506 |
| HypertensionVascular disorders | 23/1510 | 22/1506 |
| Chest PainGeneral disorders | 11/1510 | 19/1506 |
| CoughRespiratory, thoracic and mediastinal disorders | 16/1510 | 14/1506 |
| Age, Continuous(years) | Rivaroxaban 2.5 mg Twice Daily (BID) | Acetylsalicylic Acid 100 mg Once Daily (OD) | Total |
|---|---|---|---|
| Mean | 62.7 ± 9.14 | 62.9 ± 8.82 | 62.8 ± 8.98 |
| Sex: Female, Male(Participants) | Rivaroxaban 2.5 mg Twice Daily (BID) | Acetylsalicylic Acid 100 mg Once Daily (OD) | Total |
|---|---|---|---|
| Female | 385 | 377 | 762 |
| Male | 1134 | 1141 | 2275 |
| Race/Ethnicity, Customized(Participants) | Rivaroxaban 2.5 mg Twice Daily (BID) | Acetylsalicylic Acid 100 mg Once Daily (OD) | Total |
|---|---|---|---|
| White | 1417 | 1407 | 2824 |
| Black | 24 | 16 | 40 |
| Asian | 54 | 63 | 117 |
| Others | 24 | 32 | 56 |
| Region of Enrollment(participants) | Rivaroxaban 2.5 mg Twice Daily (BID) | Acetylsalicylic Acid 100 mg Once Daily (OD) | Total |
|---|---|---|---|
| ARGENTINA | 66 | 65 | 131 |
| AUSTRALIA | 18 | 17 | 35 |
| BELGIUM | 49 | 40 | 89 |
| BRAZIL | 77 | 85 | 162 |
| BULGARIA | 83 | 78 | 161 |
| CANADA | 37 | 47 | 84 |
| CZECH REPUBLIC | 34 | 37 | 71 |
| DENMARK | 1 | 2 | 3 |
| FRANCE | 28 | 29 | 57 |
| HUNGARY | 101 | 100 | 201 |
| ITALY | 75 | 59 | 134 |
| JAPAN | 26 | 33 | 59 |
| NETHERLANDS | 69 | 65 | 134 |
| POLAND | 158 | 175 | 333 |
| RUSSIA | 237 | 244 | 481 |
| SPAIN | 62 | 60 | 122 |
| SWEDEN | 42 | 37 | 79 |
| TURKEY | 102 | 98 | 200 |
| UKRAINE | 137 | 129 | 266 |
| UNITED STATES | 93 | 88 | 181 |
| Korea, Republic Of | 24 | 30 | 54 |
Showing the first 100 of 262 sites across 20 countries. Choose a country and city above to see the rest.
Ran from Apr 2015 to primary completion in Oct 2016, 17 months.
Results were first posted in Nov 2017, 1 year after primary completion.
Of 30 phase 2 interventional studies under Acute Coronary Syndrome, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rivaroxaban · Clopidogrel · Ticagrelor
Janssen Research & Development, LLC →